EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. (Q40684657)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

title

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Raashid Ahmed Luqmani

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Alfred D Mahr

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Richard A Watts

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

Chetan Mukhtyar

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

author name string

M Yates

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

I M Bajema

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

M C Cid

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

B Crestani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

T Hauser

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

B Hellmich

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

J U Holle

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

M Laudien

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

P A Merkel

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

J Mills

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

J Mooney

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

M Segelmark

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

K Westman

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

A Vaglio

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

N Yalçındağ

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

D R Jayne

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

V Tesar

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

language of work or name

English

0 references

publication date

23 June 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

Annals of the Rheumatic Diseases

15 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

volume

75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

page(s)

1583-1594

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

15 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Prevalence and incidence of Wegener's granulomatosis in the UK general practice research database

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

EULAR recommendations for the management of primary small and medium vessel vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Does geographic location affect incidence of ANCA-associated renal vasculitis in northern Saskatchewan, Canada?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Wegener's granulomatosis--increased incidence or increased recognition?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Dilatation tracheoscopy for laryngeal and tracheal stenosis in patients with Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Wegener Granulomatosis: An Analysis of 158 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Long-term patient survival in ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Real-time ultrasound-guided percutaneous renal biopsy with needle guide by nephrologists decreases post-biopsy complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Bleeding complications of native kidney biopsy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Histopathologic classification of ANCA-associated glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

The new histopathologic classification of ANCA-associated GN and its association with renal outcomes in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Cyclophosphamide Therapy in Wegener's Granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Cyclophosphamide pulse therapy in Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Cyclophosphamide-induced bladder toxicity in wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Effect of delayed diagnosis on disease course and management of Churg-Strauss syndrome: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Wegener's granulomatosis in Finland in 1981-2000: clinical presentation and diagnostic delay

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Simple urine testing could avoid delay in the diagnosis of rapidly progressive glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Etanercept plus standard therapy for Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Clinical features and outcome of patients with both ANCA and anti-GBM antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Rituximab for the treatment of Churg-Strauss syndrome with renal involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

The informational needs of patients with ANCA-associated vasculitis-development of an informational needs questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Explaining fatigue in ANCA-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

The characterisation and determinants of quality of life in ANCA associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209133

10.1136/ANNRHEUMDIS-2016-209133

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27338776%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference